Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain games may beat chemo fog

NCT ID NCT05283629

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether special computer-based brain exercises can improve memory, concentration, and thinking in breast cancer survivors who have ongoing mental fogginess after chemotherapy. About 50 women aged 35 to 80 who finished chemo 1 to 8 years ago will either do the brain training or receive education only for 6 weeks. The goal is to see if the training reduces their cognitive complaints and improves test performance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2022

Expected to finish

Mar 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: All participants will: * between 35 and 80 years of age * have been diagnosed with noninvasive or invasive breast cancer * have undergone treatment with systemic chemotherapy within the last 1- 8 years * endorse persistent CRCI subjective complaints * have no active unstable medical condition * fluent in and able to read English. Exclusion Criteria: Participants will be excluded for * any active neurologic or untreated/non-remitted psychiatric disease, (e.g. active major depression or another major psychiatric disorder as described in DSM-5) * clinically significant cognitive impairment identified on cognitive screening, diagnosis of mild cognitive impairment or dementia * history of significant head trauma followed by persistent neurologic deficits * history of alcohol or substance abuse or dependence within the past 2 years (DSM-5 criteria) * any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol * Use of any investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to screening * red-green color blindness * Use of certain CNS active medications (e.g. antidepressants) will be permitted, provided dosing has been stable for at least 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chemo brain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Chemotherapy-Related Cognitive Impairment Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UMass Chan Medical School

    Worcester, Massachusetts, 01655, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.